Abstract:Background: Cancer and cardiovascular diseases are the main causes of mortality worldwide. Although the incidence of cancer is rising, modern comprehensive management including surgery, chemotherapy, and radiotherapy led to decreased mortality, but also different cardiovascular complications. Conventional EF measurement fails to detect subtle changes in LV function, so a more sensitive tool is needed. Methods: The study included 101 asymptomatic female patients with newly diagnosed breast cancer who received anthracycline ± trastuzumab-based chemotherapy regimen. A comprehensive echocardiographic examination was performed before receiving the chemotherapy (T0), at 3 months (T1), and at 6 months after (T2). All patients had pre-treatment normal LV EF. Asymptomatic CTRCD is defined as: severe if new LVEF reduction to < 40%, moderate if new LVEF reduction by ≥ 10 percentage points to an LVEF of 40-49% or new LVEF reduction by, 10 percentage points to an LVEF of 40- 49% and either new relative decline in GLS by .15% from baseline or new rise in cardiac biomarkers and mild if LVEF ≥ 50% and new relative decline in GLS by .15% from baseline and/or new rise in cardiac biomarkers. Symptomatic CTRCD is defined as: very severe if HF requiring inotropic support, mechanical circulatory support, or consideration of transplantation, severe if required hospitalization, moderate if required outpatient intensification of diuretic and HF therapy and mild if there are mild HF symptoms and no intensification of therapy required according to the latest ESC cardio oncology guidelines. The Lower reference value set for RV S' was less than 10cm/s to define RV systolic dysfunction according to ASE guidelines. Results: CTRCD occurred in 24 patients (25.5%) while RV systolic dysfunction was more common occurring in 37 patients (39.4%). LV GLS at (T1) (cut-off value < -15% with relative 12.5% reduction from the baseline value) was a strong predictor of CTRCD, but combining LV GLS with RV GLS & RV FWLS was the strongest (AUC = 0.947, sensitivity = 91.67%, specificity = 90%). Conclusion: Chemotherapy induces biventricular changes with more prevalent deterioration in RV values. Low LV & RV strain values at baseline together with reduction of these values after chemotherapy treatment can predict later CTRCD development. Combining LV GLS with RV GLS & FWLS values at (T1) is the strongest predictor of subsequent CTRCD.

Early Detection and Prediction of Anthracycline-Induced Right Ventricular Cardiotoxicity by 3-Dimensional Echocardiography

Right Ventricular Ejection Fraction Assessed by Three-Dimensional Echocardiography Is Associated with Long-Term Adverse Clinical Cardiac Events in Patients with Anthracycline-Induced Cardiotoxicity

Routine first-line detection of breast cancer therapy-related cardiotoxicity by serial, fast and ultra-low-dose equilibrium radionuclide angiography

Prediction of Cardiovascular Adverse Events in Patients Treated with R-CHOP Regimens by 3D Transthoracic Echocardiography

3D echocardiography and biomarkers for early diagnosis and prediction of chemotherapy induced right ventricular dysfunction in non-Hodgkin lymphoma patients

Three-Dimensional Speckle Tracking Echocardiography for Assessment of Right Ventricular Morphological Changes and Dysfunction on Long-term Lymphoma Survivors Received Anthracycline Therapy

Three-Dimensional Speckle-Tracking Echocardiography to Evaluate Left Ventricular Function of Patients with Breast Cancer After Anthracycline Chemotherapy

Early Detection of Left Ventricular Dysfunction in Patients with Esophageal Cancer During Concurrent Chemoradiotherapy by Real-Time Three-Dimensional Speckle Tracking Echocardiography

Prognostic Value of Right Ventricular 3D Speckle-Tracking Strain and Ejection Fraction in Patients With HFpEF

Early detection of cardiotoxicity by 3D speckle tracking imaging of area strain in breast cancer patients receiving chemotherapy

Early detection of chemotherapy-induced cardiotoxicity in breast cancer patients: a comprehensive analysis using speckle tracking echocardiography

Evaluation of Right Ventricular Myocardial Mechanics by 2- and 3-Dimensional Speckle-Tracking Echocardiography in Patients With an Ischemic or Non-ischemic Etiology of End-Stage Heart Failure

Evaluation of the left ventricular myocardial dysfunction in patients with breast cancer after receiving Anthracycline by three-dimensional speckle tracking imaging

Assessment of Biventricular Systolic Strain Derived from the Two-Dimensional and Three-Dimensional Speckle Tracking Echocardiography in Lymphoma Patients after Anthracycline Therapy

Evaluation of Subclinical Dysfunction of Left Ventricle Induced by Anthracycline in Patients with Lymphoma by ;Two-Dimensional Speckle Tracking Echocardiography and Real-Time Three-Dimensional Echocardiography

Use of echocardiography to monitor myocardial damage during anthracycline chemotherapy

Evaluation of Left Ventricular Function with Left Atrio-Ventricular Longitudinal Strain in Patients with Lymphoma Underwent Anthracycline Therapy

Evaluation of Subclinical Dysfunction of Left Ventricle Induced by Anthracyclines in Patients with Diffuse Large B-cell Lymphoma by Real-Time Three Dimensional Echocardiography

Early Detection of Anthracycline-Induced Cardiotoxicity Using Two-Dimensional Speckle Tracking Echocardiography.

Right ventricle toxicity in cancer treatment: a focused review on cardiac imaging

Two-dimensional speckle tracking echocardiography in chemotherapy-induced cardiotoxicity in females with breast cancer